Status:
UNKNOWN
Effect of Fatty Liver Disease on Bone Density
Lead Sponsor:
Sohag University
Conditions:
Non-Alcoholic Fatty Liver Disease
Osteoporosis
Eligibility:
All Genders
20-60 years
Brief Summary
Non Alcohlic Fatty Liver (NAFLD) is a spectrum of diseases that ranges from accumulation of fat in the liver (Hepatosteatosis) that may be accompanied by inflammation (Steatohepatitis) to necrosis, fi...
Detailed Description
All included patients will be subjected to the following: 1. Complete history taking including age, sex, current medical history (e.g. hypertension, diabetes mellitus, cardiovascular disease, renal, ...
Eligibility Criteria
Inclusion
- Males (20-60 years old ) and premenopausal females with NAFLD diagnosed by Fibroscan
Exclusion
- (i) Patients aged \<20 years or \>60years. (ii) Alcohol consumption of ≥30 g/day in men or≥20 g/day in women. (iii) Subjects with suspected or proven any other liver disease other than NAFLD as (viral hepatitis, drug-induced liver injury, autoimmune liver disease, Wilson's disease or primary biliary cholangitis).
- (iv) Postmenopausal females to avoid the increased risk of osteoporosis in those patients due to hormonal changes.
- (v) Patients with conditions known to affect bone metabolism, such as kidney, thyroid or parathyroid diseases.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04850547
Start Date
May 1 2021
End Date
May 1 2022
Last Update
April 20 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.